Cardiovasc Drugs Ther (2017) 31:233–246 DOI 10.1007/s10557-017-6734-1 ORIGINAL ARTICLE Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes 1,2 1 1 1,3 Nadjib Hammoudi & Dongtak Jeong & Rajvir Singh & Ahmed Farhat & 2 4 1 1,3,5 Michel Komajda & Eric Mayoux & Roger Hajjar & Djamel Lebeche Published online: 22 June 2017 Springer Science+Business Media New York 2017 Abstract significantly lowered HbA1c and slightly reduced body Purpose Cardiovascular (CV) diseases in type 2 diabetes weight compared to vehicle treatment with no obvious chang- (T2DM) represent an enormous burden with high mortality es in insulin levels. Empagliflozin also improved LV maxi- and morbidity. Sodium-glucose cotransporter 2 (SGLT2) in- mum pressure and in vivo indices of diastolic function. While hibitors have recently emerged as a new antidiabetic class that systolic function was grossly not affected in both groups at improves glucose control, as well as body weight and blood steady state, response to dobutamine stimulation was signifi- pressure with no increased risk of hypoglycemia. The first CV cantly improved in the empagliflozin-treated group, suggest- outcome study terminated with empagliflozin, a specific ing amelioration of contractile reserve. This was paralleled by SGLT2 inhibitor, has shown
Cardiovascular Drugs and Therapy – Springer Journals
Published: Jun 22, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera